Theravance Biopharma, Inc. Announces Top-line Results from a Pha

44
TBPH: Theravance Biopharma, Inc.
2021-09-15 06:05:00
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.